Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical has received approval from the National Medical Products Administration for its new drug, Botulinum Toxin Type A, aimed at treating cervical dystonia in adults. This development follows their exclusive licensing agreement with Revance Therapeutics to import, use, and commercialize the drug in China, Hong Kong, and Macau. This approval marks a significant milestone for Fosun Pharma in expanding its portfolio in the pharmaceutical market.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.